Lundbeck to trial migraine drug in young people
A new phase III trial in the US will investigate whether extending the patient target group of Lundbeck's drug Vyepti to include younger patients is possible.
BY MIKKEL AABENHUS HEMMINGSEN, TRANSLATED BY CATHERINE BRETT
285 participants aged 12-17 will test Lundbeck's drug Vyepti as a preventative treatment for migraines over the next year.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Sales of Biohaven's migraine tablet exceed expectations
For subscribers
